32 results about "Angiogenic Peptides" patented technology

This invention relates to novel synthetic lytic peptide fragments of full-length peptides with the capacity to modulate angiogenic activity in mammals. The invention also relates to the use of such peptides in pharmaceutical compositions and in methods for treating diseases or disorders that are associated with angiogenic activity.

Modified anti-angiogenic peptides are disclosed. The modified peptides are capable of forming a peptidase stabilized anti-angiogenic peptide. The modified anti-angiogenic peptides, particularly modified kringle 5 peptides are capable of forming a conjugate with a blood protein. Conjugates are prepared from anti-angiogenic peptides, particularly kringle 5 peptides, by combining the peptide with a reactive functional group with a blood protein. The conjugates may be formed in vivo or ex vivo. The conjugates are administered to patients to provide an anti-angiogenic effect.

Modified anti-angiogenic peptides are disclosed. The modified peptides are capable of forming a peptidase stabilized anti-angiogenic peptide. The modified anti-angiogenic peptides, particularly modified kringle 5 peptides are capable of forming a conjugate with a blood protein. Conjugates are prepared from anti-angiogenic peptides, particularly kringle 5 peptides, by combining the peptide with a reactive functional group with a blood protein. The conjugates may be formed in vivo or ex vivo. The conjugates are administered to patients to provide an anti-angiogenic effect.

The invention generally features compositions and methods that are useful for modulating blood vessel formation, as well as methods that provide for the systematic and efficient identification of angiogenesis modulators. As described in more detail below, a systematic computational methodology based on bioinformatics was used to identify novel peptide modulators of angiogenesis that have been characterized in vitro and / or in vivo.

This present invention is directed to peptides, compositions, and methods for modulating endogenous cytokine expression in a subject. More specifically, the invention provides peptides useful in regulating the release of a specific pattern of cytokines that promote angiogenesis and / or can be used to modulate the immune system of a subject.

Unregulated angiogenesis is associated with a variety of pathological conditions. Tumor growth and metastasis is dependent on the development of new blood vessels. The development of new blood vessels in the eye, or ocular neovascularization, has been implicated in a variety of serious ocular diseases. For instance, choroidal neovascularization is linked to age-related macular degeneration, while retinal neovascularization is linked to diabetic retinopathy. The present invention is based on the discovery of a peptide sequence, C16Y, which inhibits ocular neovascularization and tumor growth in vivo. C16Y is a scrambled version of the C16 peptide sequence from the y1 chain of laminin-1. Unlike C16, which is an angiogenic stimulator, C16Y has been shown to inhibit angiogenesis. The present invention discloses methods of treating ocular neovascularization and cancer using both full-length and truncated versions of the C16Y.

Short bioactive sequences derived from the 2nd loop of the 7-transmembranal receptor of endothelial differentiation gene 3 (EDG3) useful in stimulation of angiogenesis, and peptide conjugates comprising a permeability enhancing moiety, are provided. Also provided are pharmaceutical compositions comprising the peptides and methods of use in conditions were insufficient blood-supply occurs, or which are associated with endothelia dysfunction such as peripheral vascular diseases, coronary artery diseases, cerebrovascular diseases, diabetes and delayed wound healing, pulmonary disease, eye diseases and pathological condition related to severe infection.

A peptide comprising an amino acid sequence as set forth in SEQ ID NO: 2, 4, 6, 8, 10 or 12 is provided. The peptide being at least 6 and no more than 50 amino acid residues in length. Also provided are therapeutic applications using such peptides.

The present application discloses angiogenic peptides that cause intracellular calcium release in target cells and thereby induce proliferation, migration, and capillary-like tube formation in primary cultured endothelial cells. The angiogenic peptides can be used for preventing and / or treating angiognesis-related conditions, especially wound healing, treating foot and leg ulcers in a subject, etc. In addition, the angiogenic peptides can be used for cosmetics a constituent of cosmetics for aged skin, for examples, anti-wrinkle and skin whitening.

The invention provides a detection method of angiogenesis peptide, the detection method utilizes an ultra-high performance liquid chromatography analysis method to analyze an angiogenesis peptide sample, and the ultra-high performance liquid chromatography analysis condition comprises that sodium heptanesulfonate-acetonitrile is used as a mobile phase A, acetonitrile is used as a mobile phase B, and gradient elution is carried out. The invention provides the detection method of the angiogenesis peptide, the rapid and accurate detection of the angiogenesis peptide can be realized, compared with the traditional high performance liquid chromatography analysis method, the detection time can be saved by 75%, and the separation degree between the main peak and the front and back impurities, the number of theoretical plates and the trailing factor of the method can meet the method requirements.

The invention relates to a bioactive peptide prediction method based on a deep convolutional neural network, which processes an original amino acid residue sequence through one-dimensional convolution of filters with different sizes, extracts useful features, optimizes a model through optimization model output and label cross entropy loss, and is specially designed for AAP mining and prediction. The model, namely the AAPred-CNN is based on an embedding technology but not based on features of feature engineering and manual design, data sets used for training and testing of the AAPred-CNN are a disclosed data set main and an NT15 data set, the classic deep learning algorithm TextCNN is combined with the embedding technology, residue tendency analysis and the like are applied to the prediction problem of the anti-angiogenic peptide for the first time, and the prediction accuracy of the anti-angiogenic peptide is improved. A classifier AAPred-CNN with excellent performance is designed for mining and predicting the AAP, and the AAPred-CNN is based on an embedding technology, does not depend on feature engineering, and can extract useful information from a pure amino acid residue sequence in a self-adaptive mode and is used for predicting whether polypeptide has anti-angiogenesis functional activity or not.

The present invention refers to a pharmaceutical composition comprising an isolated antiangiogenic peptide or a recombinant protein comprising the antiangiogenic peptide, wherein the peptide is between 11 and 40 amino acids in length and having antiangiogenic activity, the peptide comprising the amino acid sequence: X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14, wherein X1 is any amino acid residue compatible with forming a helix; X2 is an amino acid residue of: Leu, Ile, Val; X3 is an amino acid residue of: Arg, Lys, His, Ser, Thr; X4 is an amino acid residue of: Ile, Leu, Val; X5 is any amino acid residue compatible with forming a helix; X6 is an amino acid residue of: Leu, Ile, Val; X7 is an amino acid residue of: Leu, Ile, Val, Ser, Thr; X8 is any amino acid residue compatible with forming a helix; X9 is any amino acid residue compatible with forming a helix; X10 is an amino acid residue of: Gln, Glu, Asp, Arg, His, Lys, Asn; X11 is an amino acid residue of: Ser, Thr; X12 is an amino acid residue of: Trp, Tyr, Phe; X13 is an amino acid residue of: Leu, Ile, Val, Asn, Gln; X14 is an amino acid residue of: Glu, Gln, Asp, Asn.

The present invention provides microparticle compositions comprising antiangiogenic peptides, as well as methods of treatment, including for macular degeneration. In various aspects and embodiments, the present invention provides microparticle compositions providing extended release of anti-angiogenic peptides. The microparticle of the present invention comprises poly(lactide-co-glycolide) (PLGA)having a having lactic acid (LA) to glycolic acid (GA) ratio (LVG) of more than 1:1; the microparticle further comprises, e.g., encapsulates, an anti-angiogenic peptide derived from the alpha 5 fibrilof type IV collagen.

The present invention relates to methods and pharmaceutical compositions for the treatment of tissue lesions. The inventors showed that CCR2 is expressed on FMCs, especially on a subpopulation of progenitor cells, that they call “fetal myeloid progenitor cells” (FMPCs), and mediates the recruitment of these cells to maternal wound tissue. Moreover, the inventors reported that recruited FMCs / FMPCs improve maternal skin wound healing by organizing blood vessel endothelium and secreting pro-angiogenesis peptides, particularly chemokine CXCL1, to enhance angiogenesis in wound. In particular, the present invention relates to CCR2 agonists for use in the treatment of tissue lesions in a subject in need thereof.

This present invention is directed to peptides, compositions, and methods for modulating endogenous cytokine expression in a subject. More specifically, the invention provides peptides useful in regulating the release of a specific pattern of cytokines that promote angiogenesis and / or can be used to modulate the immune system of a subject.

Short bioactive sequences derived from the 2nd loop of the 7-transmembranal receptor of endothelial differentiation gene 3 (EDG3) useful in stimulation of angiogenesis, and peptide conjugates comprising a permeability enhancing moiety, are provided. Also provided are pharmaceutical compositions comprising the peptides and methods of use in conditions were insufficient blood-supply occurs, or which are associated with endothelia dysfunction such as peripheral vascular diseases, coronary artery diseases, cerebrovascular diseases, diabetes and delayed wound healing, pulmonary disease, eye diseases and pathological condition related to severe infection.

The invention belongs to the field of nano-drugs, and relates to an esterase response nano-drug as well as a preparation method and application thereof. The amphipathic molecules are prepared by forming an ester bond by carboxyl at the C terminal of a polypeptide molecule and hydroxyl of a drug. The polypeptide molecules are annular anti-angiogenesis peptide VGB, and the drug is oridonin ORI. The amphiphilic molecules can be self-assembled into a nano-drug in a water-phase solution under a neutral condition. The nano-drug can release VGB and ORI at a tumor part through enzyme specific enzymolysis. The nano-drug provided by the invention has the advantages of simple preparation method, no covalent bond generation in the self-assembly process, no reverse reaction, good biocompatibility, low toxic and side effects and esterase responsiveness, and has high application value and wide application prospect in preparation of nano-drugs applied to tumor resistance.